CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Intranasal Insulin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02028871
NCT02028871Phase 2Completed
CompareCT.gov

Intranasal Insulin for Weight Management During Smoking Cessation

Ajna Hamidovic·interventional·Posted Jan 7, 2014·Updated Dec 10, 2018

In Brief

A Phase 2 clinical trial evaluating Intranasal Insulin and Placebo for Tobacco Abstinence Syndrome. Completed, enrolled 26 participants across 2 sites.

Detailed Summary

This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Abstinence Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 7, 2014
Enrollment StartJul 1, 2014
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.5 years ago

Interventions

Intranasal Insulindrug

Placebodrug